[
  {
    "ts": "2025-11-04T15:31:00+00:00",
    "headline": "Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View",
    "summary": "HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.",
    "url": "https://finance.yahoo.com/news/halozyme-beats-q3-earnings-revenues-153100797.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "79210924-579f-3a8c-8861-24166c450b1c",
      "content": {
        "id": "79210924-579f-3a8c-8861-24166c450b1c",
        "contentType": "STORY",
        "title": "Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View",
        "description": "",
        "summary": "HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.",
        "pubDate": "2025-11-04T15:31:00Z",
        "displayTime": "2025-11-04T15:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kOx_hEoutoKbvEBeeXdzsA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F9I2cfbMe3krq0DVrblX.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/halozyme-beats-q3-earnings-revenues-153100797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/halozyme-beats-q3-earnings-revenues-153100797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "ARGX.BR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T12:25:16+00:00",
    "headline": "Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn",
    "summary": "Kenvue is under the microscope from the Trump administration, though Kimberly-Clark sees a $32bn horizon.",
    "url": "https://www.pharmaceutical-technology.com/news/kimberly-clark-buys-troubled-tylenol-maker-kenvue-for-48-7bn/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "22dd7210-4f9b-333a-85ec-8c7be58e3d72",
      "content": {
        "id": "22dd7210-4f9b-333a-85ec-8c7be58e3d72",
        "contentType": "STORY",
        "title": "Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn",
        "description": "",
        "summary": "Kenvue is under the microscope from the Trump administration, though Kimberly-Clark sees a $32bn horizon.",
        "pubDate": "2025-11-04T12:25:16Z",
        "displayTime": "2025-11-04T12:25:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/6951a91a36cbe5224b2dfb0a6ffae9b5",
          "originalWidth": 1000,
          "originalHeight": 750,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YRJv9zMeIE4GxNJac08PnA--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/6951a91a36cbe5224b2dfb0a6ffae9b5.cf.webp",
              "width": 1000,
              "height": 750,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dPyE7DUPcNZ_i0TRjI9rOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/6951a91a36cbe5224b2dfb0a6ffae9b5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/kimberly-clark-buys-troubled-tylenol-maker-kenvue-for-48-7bn/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-buys-troubled-tylenol-122516173.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T12:09:00+00:00",
    "headline": "$144.85 Bn Disposable Medical Device Markets, 2025-2030: Opportunities in Innovation in Sustainable Materials, and Expansion in Emerging Markets and Underserved Regions",
    "summary": "The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an",
    "url": "https://finance.yahoo.com/news/144-85-bn-disposable-medical-120900689.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "4e71172e-7075-33e1-951d-044ecd66e7bc",
      "content": {
        "id": "4e71172e-7075-33e1-951d-044ecd66e7bc",
        "contentType": "STORY",
        "title": "$144.85 Bn Disposable Medical Device Markets, 2025-2030: Opportunities in Innovation in Sustainable Materials, and Expansion in Emerging Markets and Underserved Regions",
        "description": "",
        "summary": "The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an",
        "pubDate": "2025-11-04T12:09:00Z",
        "displayTime": "2025-11-04T12:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/9516d6ebe06eb7cdd58bcc637a0a3a6e",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Disposable Medical Device Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kO73C9Y_BDdcbZBB1sXz0g--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9516d6ebe06eb7cdd58bcc637a0a3a6e.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cGrb1W5MpFU9_x3ESFOU5Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9516d6ebe06eb7cdd58bcc637a0a3a6e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/144-85-bn-disposable-medical-120900689.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/144-85-bn-disposable-medical-120900689.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T11:30:00+00:00",
    "headline": "Kimberly-Clark Takeover Offers $48 Billion of Pain Relief to Tylenol-Maker Kenvue",
    "summary": "The deal, expected to close in the second half of 2026, comes as Kenvue's Tylenol political fight is heating up.",
    "url": "https://www.thedailyupside.com/industries/consumer/kimberly-clark-acquires-kenvue-for-40-billion/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "9db6ad0c-faee-3081-abe4-34699b927b80",
      "content": {
        "id": "9db6ad0c-faee-3081-abe4-34699b927b80",
        "contentType": "STORY",
        "title": "Kimberly-Clark Takeover Offers $48 Billion of Pain Relief to Tylenol-Maker Kenvue",
        "description": "",
        "summary": "The deal, expected to close in the second half of 2026, comes as Kenvue's Tylenol political fight is heating up.",
        "pubDate": "2025-11-04T11:30:00Z",
        "displayTime": "2025-11-04T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/239ba870f025887ab304f991fd7707e9",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of boxes of Tylenol on a store shelf.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6pAPe.G2TINWF3v4vNH58w--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/239ba870f025887ab304f991fd7707e9.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/h1ez1Yhjq0_5BsD0zDAXMw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/239ba870f025887ab304f991fd7707e9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/consumer/kimberly-clark-acquires-kenvue-for-40-billion/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-takeover-offers-48-113000808.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KMB"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AMZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T11:14:10+00:00",
    "headline": "Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal",
    "summary": "Combined company aims to become global health leader by 2026.",
    "url": "https://finance.yahoo.com/news/kimberly-clark-acquire-kenvue-48-111410524.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "48cfdaea-3b3a-32a3-96e0-44a3b6dd341a",
      "content": {
        "id": "48cfdaea-3b3a-32a3-96e0-44a3b6dd341a",
        "contentType": "STORY",
        "title": "Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal",
        "description": "",
        "summary": "Combined company aims to become global health leader by 2026.",
        "pubDate": "2025-11-04T11:14:10Z",
        "displayTime": "2025-11-04T11:14:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/4130726cde7a7ee647f151f571fcfff6",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N.fGQykNhUxlTfTiHjLsKQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/4130726cde7a7ee647f151f571fcfff6.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5GWooKkPh90qV1KshR_0hA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/4130726cde7a7ee647f151f571fcfff6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-acquire-kenvue-48-111410524.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kimberly-clark-acquire-kenvue-48-111410524.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "KMB"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T10:19:15+00:00",
    "headline": "Will Pipeline Milestones and New Oral Therapies Shift Johnson & Johnson's (JNJ) Growth Narrative?",
    "summary": "In the past week, Johnson & Johnson unveiled a series of positive clinical updates and regulatory milestones for key pipeline candidates, including icotrokinra and nipocalimab, across multiple immunology and dermatology indications. The announcements featured favorable long-term efficacy and safety data, new head-to-head trials, and expanded FDA designations, indicating pipeline strength and broadening commercial opportunities. One key insight is the mounting preference among patients and...",
    "url": "https://finance.yahoo.com/news/pipeline-milestones-oral-therapies-shift-101915518.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "4d2e189f-9213-3f51-94f1-545ebebbd091",
      "content": {
        "id": "4d2e189f-9213-3f51-94f1-545ebebbd091",
        "contentType": "STORY",
        "title": "Will Pipeline Milestones and New Oral Therapies Shift Johnson & Johnson's (JNJ) Growth Narrative?",
        "description": "",
        "summary": "In the past week, Johnson & Johnson unveiled a series of positive clinical updates and regulatory milestones for key pipeline candidates, including icotrokinra and nipocalimab, across multiple immunology and dermatology indications. The announcements featured favorable long-term efficacy and safety data, new head-to-head trials, and expanded FDA designations, indicating pipeline strength and broadening commercial opportunities. One key insight is the mounting preference among patients and...",
        "pubDate": "2025-11-04T10:19:15Z",
        "displayTime": "2025-11-04T10:19:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pipeline-milestones-oral-therapies-shift-101915518.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pipeline-milestones-oral-therapies-shift-101915518.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T07:00:00+00:00",
    "headline": "Tulyp Medical Emerges From Sofinnova’s Medtech Accelerator and Announces FDA Submission Following Initial First-in-Human Use",
    "summary": "PARIS, November 04, 2025--Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted its 510(k) application to the U.S. Food and Drug Administration (FDA). The company’s debut follows positive results from its initial first-in-human study.",
    "url": "https://finance.yahoo.com/news/tulyp-medical-emerges-sofinnova-medtech-070000930.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "bfb6fe8c-7c02-3372-8a1e-12d120064196",
      "content": {
        "id": "bfb6fe8c-7c02-3372-8a1e-12d120064196",
        "contentType": "STORY",
        "title": "Tulyp Medical Emerges From Sofinnova’s Medtech Accelerator and Announces FDA Submission Following Initial First-in-Human Use",
        "description": "",
        "summary": "PARIS, November 04, 2025--Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted its 510(k) application to the U.S. Food and Drug Administration (FDA). The company’s debut follows positive results from its initial first-in-human study.",
        "pubDate": "2025-11-04T07:00:00Z",
        "displayTime": "2025-11-04T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c4affdbbb4ba33855a95f488b8194970",
          "originalWidth": 480,
          "originalHeight": 229,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UvLKlB4fhuCJ05HA50oECQ--~B/aD0yMjk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c4affdbbb4ba33855a95f488b8194970.cf.webp",
              "width": 480,
              "height": 229,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/29SZMYcrBhGK4fUxnGG52A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c4affdbbb4ba33855a95f488b8194970.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tulyp-medical-emerges-sofinnova-medtech-070000930.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tulyp-medical-emerges-sofinnova-medtech-070000930.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-04T07:00:00+00:00",
    "headline": "Alvotech faces FDA setback for its Simponi biosimilar AVT05",
    "summary": "The proposed biosimilar to J&J’s Simponi was rejected by the FDA due to manufacturing concerns.",
    "url": "https://www.pharmaceutical-technology.com/news/alvotech-faces-fda-setback-for-its-simponi-biosimilar-avt05/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "0fd95514-ebfb-3112-836d-1e460d5d977c",
      "content": {
        "id": "0fd95514-ebfb-3112-836d-1e460d5d977c",
        "contentType": "STORY",
        "title": "Alvotech faces FDA setback for its Simponi biosimilar AVT05",
        "description": "",
        "summary": "The proposed biosimilar to J&J’s Simponi was rejected by the FDA due to manufacturing concerns.",
        "pubDate": "2025-11-04T07:00:00Z",
        "displayTime": "2025-11-04T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/3eb44e54a69f29240526ed2d45daddd3",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yBqSxQJT5ROYsv_1YlRYkw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/3eb44e54a69f29240526ed2d45daddd3.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/c2KuG5_pKbOFlmzCK3BcHg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/3eb44e54a69f29240526ed2d45daddd3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/alvotech-faces-fda-setback-for-its-simponi-biosimilar-avt05/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/alvotech-faces-fda-setback-simponi-070000105.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALVO"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]